Randomized controlled trial demonstrates nutritional management is … – avmajournals.avma.org

Advertisement
.avma_container { background: #ddd; width: 100%; padding: 0; margin: 0; opacity: 1; display: flex; } .avma_container div{ display: flex; height: 10px; padding: 0; margin: 0; } .item01 { background: #EBF6F7; width: 100%; }
Berset-Istratescu CM, Glardon OJ, Magouras I, Frey CF, Gobeli S, Burgener IA. Follow-up of 100 dogs with acute diarrhoea in a primary care practice. Vet J. 2014;199(1):188–190. doi:10.1016/j.tvjl.2013.10.014
Saevik BK, Skancke EM, Trangerud C. A longitudinal study on diarrhoea and vomiting in young dogs of four large breeds. Acta Vet Scand. 2012;54:8. doi:10.1186/1751-0147-54-8
Hubbard K, Skelly BJ, McKelvie J, Wood JL. Risk of vomiting and diarrhoea in dogs. Vet Rec. 2007;161(22):755–757. doi:10.1136/vr.161.22.755
Stavisky J, Radford AD, Gaskell R, et al. A case-control study of pathogen and lifestyle risk factors for diarrhoea in dogs. Prev Vet Med. 2011;99(2–4):185–192. doi:10.1016/j.prevetmed.2011.02.009
Lappin MR, Zug A, Hovenga C, Gagne J, Cross E. Efficacy of feeding a diet containing a high concentration of mixed fiber sources for management of acute large bowel diarrhea in dogs in shelters. J Vet Intern Med. 2022;36(2):488–492. doi:10.1111/jvim.16360
Grove DI, Mahmound AA, Warren KS. Suppression of cell-mediated immunity by metronidazole. Int Arch Allergy Appl Immunol. 1977;54(5):422–427. doi:10.1159/000231857
Lee JA. Metronidazole risks. Clin Brief. Published online September 2014. Accessed March 7, 2022. https://www.cliniciansbrief.com/article/metronidazole-risks
Fitzgerald K. Metronidazole. In: Peterson D, Talcott P, eds. Small Animal Toxicology. 3rd ed. Saunders Elsevier; 2013:653–658.
Dow SW, LeCouteur RA, Poss ML, Beadleston D. Central nervous system toxicosis associated with metronidazole treatment of dogs: five cases (1984–1987). J Am Vet Med Assoc. 1989;195(3):365–368.
Evans J, Levesque D, Knowles K, Longshore R, Plummer S. Diazepam as a treatment for metronidazole toxicosis in dogs: a retrospective study of 21 cases. J Vet Intern Med. 2003;17(3):304–310. doi:10.1111/j.1939-1676.2003.tb02452.x
Sekis I, Ramstead K, Rishniw M, et al. Single-dose pharmacokinetics and genotoxicity of metronidazole in cats. J Feline Med Surg. 2009;11(2):60–68. doi:10.1016/j.jfms.2008.06.011
Pilla R, Gaschen FP, Barr JW, et al. Effects of metronidazole on the fecal microbiome and metabolome in healthy dogs. J Vet Intern Med. 2020;34(5):1853–1866. doi:10.1111/jvim.15871
Chaitman J, Ziese AL, Pilla R, et al. Fecal microbial and metabolic profiles in dogs with acute diarrhea receiving either fecal microbiota transplantation or oral metronidazole. Front Vet Sci. 2020;7:192.
Mendelson M. Role of antibiotic stewardship in extending the age of modern medicine. S Afr Med J. 2015;105(5):414–418. doi:10.7196/SAMJ.9635
Mohr AJ, Leisewitz AL, Jacobson LS, Steiner JM, Ruaux CG, Williams DA. Effect of early enteral nutrition on intestinal permeability, intestinal protein loss, and outcome in dogs with severe parvoviral enteritis. J Vet Intern Med. 2003;17(6):791–798. doi:10.1111/j.1939-1676.2003.tb02516.x
Nelson RW, Stookey LJ, Kazacos E. Nutritional management of idiopathic chronic colitis in the dog. J Vet Intern Med. 1988;2(3):133–137. doi:10.1111/j.1939-1676.1988.tb02809.x
Leib MS. Treatment of chronic idiopathic large-bowel diarrhea in dogs with a highly digestible diet and soluble fiber: a retrospective review of 37 cases. J Vet Intern Med. 2000;14(1):27–32. doi:10.1111/j.1939-1676.2000.tb01495.x
Allenspach K, Wieland B, Grone A, Gaschen F. Chronic enteropathies in dogs: evaluation of risk factors for negative outcome. J Vet Intern Med. 2007;21(4):700–708. doi:10.1111/j.1939-1676.2007.tb03011.x
Simpson JM, Maskell IE, Markwell, PJ. Use of a restricted antigen diet in the management of idiopathic canine colitis. J Small Anim Pract. 1994;35:234.
Yee H, Arruda AG, Rudinsky AJ, Iazbik C, Millward L, Marsh A. Risk factors and impact of COVID-19-related clinic closures on the detection of gastrointestinal parasites in dogs, a cross-sectional study. Vet Parasitol Reg Stud Reports. 2021;26:100647. doi:10.1016/j.vprsr.2021.100647
AlShawaqfeh MK, Wajid B, Minamoto Y, et al. A dysbiosis index to assess microbial changes in fecal samples of dogs with chronic inflammatory enteropathy. FEMS Microbiol Ecol. 2017;93(11):fix136. doi:10.1093/femsec/fix136
Waltham faeces scoring system. Waltham. Accessed January 1, 2019. https://www.waltham.com/dyn/_assets/_pdfs/other-resources/waltham-scoring.pdf
Wernimont SM, Radosevich J, Jackson MI, et al. The effects of nutrition on the gastrointestinal microbiome of cats and dogs: impact on health and disease. Front Microbiol. 2020;11:1266.
Bontempo V. Nutrition and health of dogs and cats: evolution of petfood. Vet Res Commun. 2005;29(suppl 2):45–50. doi:10.1007/s11259-005-0010-8
Langlois DK, Koenigshof AM, Mani R. Metronidazole treatment of acute diarrhea in dogs: a randomized double blinded placebo-controlled clinical trial. J Vet Intern Med. 2020;34(1):98–104. doi:10.1111/jvim.15664
Shmalberg J, Montalbano C, Morelli G, Buckley GJ. A randomized double blinded placebo-controlled clinical trial of a probiotic or metronidazole for acute canine diarrhea. Front Vet Sci. 2019;6:163. doi:10.3389/fvets.2019.00163
Fenimore A, Martin L, Lappin MR. Evaluation of metronidazole with and without Enterococcus faecium SF68 in shelter dogs with diarrhea. Top Companion Anim Med. 2017;32(3):100–103. doi:10.1053/j.tcam.2017.11.001
Pignataro G, Di Prinzio R, Crisi PE, et al. Comparison of the therapeutic effect of treatment with antibiotics or nutraceuticals on clinical activity and the fecal microbiome of dogs with acute diarrhea. Animals (Basel). 2021;11(6):1484. doi:10.3390/ani11061484
Gobeli S, Berset C, Burgener I, Perreten V. Antimicrobial susceptibility of canine Clostridium perfringens strains from Switzerland. Schweiz Arch Tierheilkd. 2012;154(6):247–250. doi:10.1024/0036-7281/a000340
Marks SL, Rankin SC, Byrne BA, Weese JS. Enteropathogenic bacteria in dogs and cats: diagnosis, epidemiology, treatment, and control. J Vet Intern Med. 2011;25(6):1195–1208. doi:10.1111/j.1939-1676.2011.00821.x
Fujishiro MA, Lidbury JA, Pilla R, Steiner JM, Lappin MR, Suchodolski JS. Evaluation of the effects of anthelmintic administration on the fecal microbiome of healthy dogs with and without subclinical Giardia spp. and Cryptosporidium canis infections. PLoS One. 2020;15(2):e0228145. doi:10.1371/journal.pone.0228145
Bamias G, Marini M, Moskaluk CA, et al. Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn’s disease. J Immunol. 2002;169(9):5308–5314. doi:10.4049/jimmunol.169.9.5308
Sadowska A, Kretowski R, Szynaka B, Cechowska-Pasko M, Car H. Metronidazole decreases viability of DLD-1 colorectal cancer cell line. Cancer Biother Radiopharm. 2013;28(8):615–622. doi:10.1089/cbr.2013.1485
Tauro A, Beltran E, Cherubini GB, et al. Metronidazole-induced neurotoxicity in 26 dogs. Aust Vet J. 2018;96(12):495–501. doi:10.1111/avj.12772
Suchodolski JS, Markel ME, Garcia-Mazcorro JF, et al. The fecal microbiome in dogs with acute diarrhea and idiopathic inflammatory bowel disease. PLoS One. 2012;7(12):e51907. doi:10.1371/journal.pone.0051907
Igarashi H, Maeda S, Ohno K, Horigome A, Odamaki T, Tsujimoto H. Effect of oral administration of metronidazole or prednisolone on fecal microbiota in dogs. PLoS One. 2014;9(9):e107909. doi:10.1371/journal.pone.0107909
Bartlett JG. Clinical practice: antibiotic-associated diarrhea. N Engl J Med. 2002;346(5):334–339. doi:10.1056/NEJMcp011603
Advertisement
To describe the outcome of dietary management of canine noninfectious acute colitis with or without concurrent oral administration of metronidazole using a randomized controlled clinical trial.
59 client-owned dogs with noninfectious acute colitis.
Dogs with acute noninfectious colitis were enrolled in a 30-day diet trial after exclusion of parasitic infectious etiologies (fecal centrifugation floatation, Giardia/Cryptosporidium antigen testing) and systemic disease (CBC, biochemistry, urinalysis). Dogs were randomized into 3 placebo-controlled groups: group 1, easily digestible diet + placebo tablet; group 2, easily digestible diet + metronidazole tablet; and group 3, psyllium-enhanced easily digestible diet + placebo tablet. Dogs were evaluated serially using fecal scoring for time to remission, average fecal score, relapse after remission, and dysbiosis index.
Median remission time was significantly different among the 3 groups (P < .01) with median times of 5 days (range, 4 to 10) for group 1, 8.5 days (range, 7 to 12) for group 2, and 5 days (range, 3 to 6) for group 3. Metronidazole addition affected the fecal dysbiosis index negatively at days 7 to 10. No adverse effects or complications were noted throughout the study.
For canine noninfectious acute colitis, dietary management with an easily digestible diet with or without psyllium enhancement proved a superior management strategy compared to metronidazole. The omission of metronidazole reduced the adverse impact significantly on intestinal microbiota. Longitudinal clinical trials are necessary to compare the long-term response, stability, and complications associated with dietary management alone versus combined dietary and antimicrobial therapy for canine acute colitis.
To describe the outcome of dietary management of canine noninfectious acute colitis with or without concurrent oral administration of metronidazole using a randomized controlled clinical trial.
59 client-owned dogs with noninfectious acute colitis.
Dogs with acute noninfectious colitis were enrolled in a 30-day diet trial after exclusion of parasitic infectious etiologies (fecal centrifugation floatation, Giardia/Cryptosporidium antigen testing) and systemic disease (CBC, biochemistry, urinalysis). Dogs were randomized into 3 placebo-controlled groups: group 1, easily digestible diet + placebo tablet; group 2, easily digestible diet + metronidazole tablet; and group 3, psyllium-enhanced easily digestible diet + placebo tablet. Dogs were evaluated serially using fecal scoring for time to remission, average fecal score, relapse after remission, and dysbiosis index.
Median remission time was significantly different among the 3 groups (P < .01) with median times of 5 days (range, 4 to 10) for group 1, 8.5 days (range, 7 to 12) for group 2, and 5 days (range, 3 to 6) for group 3. Metronidazole addition affected the fecal dysbiosis index negatively at days 7 to 10. No adverse effects or complications were noted throughout the study.
For canine noninfectious acute colitis, dietary management with an easily digestible diet with or without psyllium enhancement proved a superior management strategy compared to metronidazole. The omission of metronidazole reduced the adverse impact significantly on intestinal microbiota. Longitudinal clinical trials are necessary to compare the long-term response, stability, and complications associated with dietary management alone versus combined dietary and antimicrobial therapy for canine acute colitis.

Follow JAVMA
Follow AJVR
Follow the AVMA
Subscribe to newsletters
 
© 2022 American Veterinary Medical Association. All rights reserved.
Powered by KGL PubFactory
Character limit 500/500
Character limit 500/500

source